Multimeric complexes of antigens and an adjuvant

Details Multimeric complexes of antigens and an adjuvant Multimeric complexes of antigens and an adjuvant

2011-05-31

2011-05-31

Stucker, Jeffrey (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S194100, C530S350000, C530S403000, C435S069100, C536S023500

Reexamination Certificate

active

07951376

ABSTRACT:
The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.

REFERENCES:
patent: WO 91/11461 (1991-08-01), None
patent: WO 2004/016283 (2004-02-01), None
patent: WO 2004/020639 (2004-03-01), None
patent: WO 2005/014654 (2005-02-01), None
patent: WO 2005/051414 (2005-08-01), None
patent: WO 2005/077976 (2005-08-01), None
Oshimui et al, Journal of Immunology, 2005, vol. 175, pp. 1724-1734.
Guidry et al., “Probing the interface in a human co-chaperonin heptamer: . . . ,”BMC Biochemistry4:14-26 (2003).
Hillarp et al., “Molecular cloning of rat C4b binding protein alpha- and beta-chains: . . . ,”J. Immun., 158(3):1315-1323 (1997).
Kaidoh et al., “Phylogeny of C4B-C3B Cleaving Activity Similar Fragmentation Patterns of Human C4B and C3B Produced by Lower Animals,”J. Immun., 139(1):194-201 (1987).
Kawabata et al., “Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms ofPlasmodium yoellii,” Infection and Immunity, 70(11):6075-6082 (2002).
Lintin et al., “Derivation of the Sequence of the Signal Peptide in Human C4B-Binding Protein and Interspecies Cross-Hybridization of the C4BP Complementary DNA Sequence,”FEBS Letters, 232(2):328-332 (1988).
Liu et al., “High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity,”Vaccine, 23(3):366-371 (2004).
Llorca et al., “Role of the amino terminal domain in GroES oligomerization,”Biochem. Biophysica Acta1337:47-56 (1997).
Oshiumi et al., “Regulator of Complement Activation (RCA) Locus in Chicken: . . . ,”J. Immunol., 175:1724-1734 (2005).
Ostro and Cullis, “Use of liposomes as injectable-drug delivery systems,”Am. J. Hosp. Pharm., 46:1576 (1989).
Seale and Horowitz, “The C-terminal Sequence of the Chaperonin GroES is Required for Oligomerization,”J. Biol. Chem., 270:30268-30270 (1995).
Office Action relating to corresponding EP Application No.: 06829178.0.
Ogun, et al., “The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused with the Murine C4bp Domain Protects Mice Against Malaria,” Infection and Immunity, Aug. 2008, vol. 76, No. 8, 3817-3823.

Affiliated with

Also associated with

Rating

Multimeric complexes of antigens and an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multimeric complexes of antigens and an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multimeric complexes of antigens and an adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2687569